Cleared Traditional

K172416 - Synermed Opiate Enzyme Immunoassay

K172416 is an FDA 510(k) clearance for Synermed Opiate Enzyme Immunoassay, manufactured by Infrared Laboratory Systems, LLC (Dba Synermed). The device is a Class 2 Toxicology device with product code DJG cleared through the Traditional 510(k) pathway after a 252-day FDA review.

K172416 · Infrared Laboratory Systems, LLC (Dba Synermed) · Toxicology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 2018
Decision
252d
Days
Class 2
Risk

K172416 is an FDA 510(k) clearance for the Synermed Opiate Enzyme Immunoassay. Classified as Enzyme Immunoassay, Opiates (product code DJG), Class II - Special Controls.

Submitted by Infrared Laboratory Systems, LLC (Dba Synermed) (Westfield, US). The FDA issued a Cleared decision on April 19, 2018 after a review of 252 days - an extended review cycle.

This device falls under the Toxicology FDA review panel, regulated under 21 CFR 862.3650 - the FDA toxicology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Toxicology review framework, consistent with the majority of Class II 510(k) submissions.

View all Infrared Laboratory Systems, LLC (Dba Synermed) devices

FDA 510(k) Submission Details - K172416

510(k) Number K172416 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 10, 2017
Decision Date April 19, 2018
Days to Decision 252 days
Submission Type Traditional
Review Panel Toxicology (TX)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
165d slower than avg
Panel avg: 87d · This submission: 252d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

DJG Device Classification - Class 2, Special Controls

Product Code DJG Enzyme Immunoassay, Opiates
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3650
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Toxicology devices follow this clearance model.

Regulatory Peers - DJG Enzyme Immunoassay, Opiates

All 162
Devices cleared under the same product code (DJG) and FDA review panel - the closest regulatory comparables to K172416.
ARK Tramadol Assay
K182280 · ARK Diagnostics, Inc. · Dec 2018
LZI Fentanyl Enzyme Immunoassay
K181159 · Lin-Zhi International, Inc. · Dec 2018
ARK Fentanyl Assay
K180427 · ARK Diagnostics, Inc. · Jun 2018
DRI Hydrocodone Assay
K173195 · Microgenics Corporation · Feb 2018
CEDIA Heroin Metabolite (6-AM) Assay
K173183 · Microgenics Corporation · Nov 2017
Emit II Plus Oxycodone Assay
K172910 · Siemens Healthcare Diagnostics, Inc. · Oct 2017